Is lecanemab the Alzheimer’s drug that will finally make a difference?

(By Jon Hamilton for NPR)

A drug that offers a small benefit to Alzheimer’s patients is making a big splash with doctors who treat the disease.

The drug, a monoclonal antibody called lecanemab, dominated last week’s Clinical Trials on Alzheimer’s Disease meeting in San Francisco. Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org